Recurrent Squamous Cell Lung Carcinoma Active Not Recruiting Phase 2 / 3 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0044226 (Recurrent Squamous Cell Lung Carcinoma)Active Not Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02766335Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersTreatment
NCT02154490Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerTreatment